---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-233581"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:32:07.955431+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences CMO/President Dr. Cindy Jacobs resigns; stays as consultant through NDA approval

## Summary
- Dr. Jacobs resigned as Chief Medical Officer and President effective Oct 6, 2025.
- Separation agreement includes lump-sum cash severance of $101,296 (prorated 2025 bonus).
- She will serve as consultant until first business day after FDA NDA approval for cytisinicline.
- Unvested time-based options from Jan 2023/Jan 2024 to accelerate upon consultancy end; exercise period extended to 12 months.
- Company will reimburse up to $10,000 in legal fees for negotiation of separation and consulting agreements.

## SEC filing metadata
- accession: 0001193125-25-233581
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000119312525233581/0001193125-25-233581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000119312525233581/achv-20251006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-233581
- JSON: https://secwatch.observer/filing/0001193125-25-233581.json
- Plain text: https://secwatch.observer/filing/0001193125-25-233581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.